Cancer News and Research

Latest Cancer News and Research

New combo drug helps suppress hepatitis C genotype 1 infection

A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist.

19 Jan 2012

New colorectal cancer screening test is highly accurate and more sensitive: Study

Results of two studies suggest that a new, investigational colorectal cancer screening test developed in a collaboration between Mayo Clinic and Exact Sciences Inc. of Madison, Wis., is highly accurate and significantly more sensitive than other noninvasive tests at detecting precancerous tumors (adenomas) and early-stage cancer.

19 Jan 2012

Exposure to metformin may decrease risk of cancer

In 2005, news first broke that researchers in Scotland found unexpectedly low rates of cancer among diabetics taking metformin, a drug commonly prescribed to patients with Type II diabetes. Many follow-up studies reported similar findings, some suggesting as much as a 50-per-cent reduction in risk.

19 Jan 2012

Study identifies mechanism that AML cells use to evade chemotherapy

A study published this week in the journal Leukemia identifies a mechanism that acute myeloid leukemia (AML) cells use to evade chemotherapy - and details how to close this escape route.

19 Jan 2012

New genetic signature could cause bile duct cancer

Investigators at the Massachusetts General Hospital (MGH) Cancer Center have identified a new genetic signature associated with bile duct cancer, a usually deadly tumor for which effective treatment currently is limited.

19 Jan 2012

Rexahn receives approval to initiate RX-3117 Phase I trial in solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for Rexahn's initial Clinical Trial Application.

19 Jan 2012

First study to examine years of life lost in Brisbane climate change

Queensland University of Technology (QUT), in collaboration with CSIRO, has conducted a world-first study into the potential impact climate change will have on 'years of life lost' in Brisbane.

19 Jan 2012

Soligenix reports results from long-term stability studies of SGX204 anthrax vaccine

Soligenix, Inc., a development stage biopharmaceutical company, announced today results from long-term stability studies of its proprietary DNI anthrax rPA subunit protein vaccine, known as SGX204.

19 Jan 2012

Novel technique accurately maps gene-regulation proteins

A novel technique has been developed and demonstrated at Penn State University to map the proteins that read and regulate chromosomes -- the string-like structures inside cells that carry genes.

19 Jan 2012

GSA honors researchers, educators for distinguished service in the field of genetics

The Genetics Society of America (GSA) is pleased to announce the 2012 recipients of its five awards for distinguished service in the field of genetics. The recipients of these awards were nominated and selected by their colleagues.

19 Jan 2012

Scientists crack genetic code for Schistosoma haematobium

Scientists have cracked the genetic code and predicted some high priority drug targets for the blood parasite Schistosoma haematobium, which is linked to bladder cancer and HIV/ AIDS and causes the insidious urogenital disease schistosomiasis haematobia in more than 112 million people in Africa.

19 Jan 2012

Book outlines digital future of medicine

The inventions of cell phones, personal computers, and the Internet ushered in the digital revolution and altered our existence in ways that were unimaginable just a few decades ago. But the most precious part of our existence-our health-has so far been largely unaffected and insulated from these innovations.

19 Jan 2012

LabCorp announces nationwide availability of Risk of Ovarian Malignancy Algorithm

Laboratory Corporation of America Holdings announced today the nationwide availability of a new FDA cleared risk stratification tool (ROMA, Risk of Ovarian Malignancy Algorithm) that combines the results for Fujirebio HE4, Abbott's ARCHITECT CA 125 II, and menopausal status into a numerical score that, along with clinical and radiological evaluation, can aid in evaluating whether a woman over the age of 18 who presents with an ovarian mass and for whom surgery is planned is at high or low likelihood of finding malignancy on surgery.

19 Jan 2012

Live interactive consultations can improve clinical outcomes for patients

UC Davis Health System dermatologists, using videoconferencing technology known as teledemedicine, have determined that live interactive consultations can improve clinical outcomes for patients because they usually involve beneficial changes in medical diagnosis and disease management that otherwise might not occur.

19 Jan 2012

Bristol-Myers Squibb agrees purchase of Inhibitex for $2.5Bn

American pharmaceutical giant Bristol-Myers Squibb has agreed the purchase of US biotech company Inhibitex, in a $2.5Bn (£1.6bn) deal which includes the promising new anti-hepatitis C drug INX-189, first designed and prepared in Cardiff University.

19 Jan 2012

USPTO issues new patent to PBL's RNAi technology

Plant Bioscience Limited (PBL) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,097,710 with fundamental claims directed to methods of inducing gene silencing using short RNA molecules, or DNA constructs encoding short RNA molecules, in a wide range of organisms, including in plants and humans.

19 Jan 2012

TB associated with EGFR mutations in patients with lung adenocarcinoma

Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease have not been extensively reported.

19 Jan 2012

EMA grants Orphan Drug Designation to Ceptaris' chlormethine gel for treatment of CTCL

Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Ceptaris' investigational drug, chlormethine gel, for the treatment of Cutaneous T-Cell Lymphoma.

18 Jan 2012

State roundup: Single-payer plans in Calif., Vt.; Calif. may regain state prison health care control; Abortion issues in Texas, Minn.

The California universal health care bill didn't make it past the Senate Appropriations Committee last year -- but Tuesday, more than 100 advocates plan to present it to the committee again, hoping for a better outcome. Under the single-payer bill, Californians would pay the state -- instead of private insurance companies -- to negotiate health care. The bill would cover any resident, including the estimated 7 million Californians who don't have health insurance now. ... A legislative health committee estimated the cost of plan would be around $200 billion.

18 Jan 2012

HRT and breast cancer – the link questioned as study flaws are reported

There is a renewed doubt over the link between hormone replacement therapy and breast cancer after researchers cast aspersions over its justification.

18 Jan 2012

Cancer News and Research

Latest Cancer News and Research

New combo drug helps suppress hepatitis C genotype 1 infection

New colorectal cancer screening test is highly accurate and more sensitive: Study

Exposure to metformin may decrease risk of cancer

Study identifies mechanism that AML cells use to evade chemotherapy

New genetic signature could cause bile duct cancer

Rexahn receives approval to initiate RX-3117 Phase I trial in solid tumors

First study to examine years of life lost in Brisbane climate change

Soligenix reports results from long-term stability studies of SGX204 anthrax vaccine

Novel technique accurately maps gene-regulation proteins

GSA honors researchers, educators for distinguished service in the field of genetics

Scientists crack genetic code for Schistosoma haematobium

Book outlines digital future of medicine

LabCorp announces nationwide availability of Risk of Ovarian Malignancy Algorithm

Live interactive consultations can improve clinical outcomes for patients

Bristol-Myers Squibb agrees purchase of Inhibitex for $2.5Bn

USPTO issues new patent to PBL's RNAi technology

TB associated with EGFR mutations in patients with lung adenocarcinoma

EMA grants Orphan Drug Designation to Ceptaris' chlormethine gel for treatment of CTCL

State roundup: Single-payer plans in Calif., Vt.; Calif. may regain state prison health care control; Abortion issues in Texas, Minn.

HRT and breast cancer – the link questioned as study flaws are reported

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in